Related Experiment Video
Updated: Jan 30, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Second re-irradiation: A delicate balance between safety and efficacy.
1Department of Oncology and Palliative Medicine, Nordland Hospital Trust, 8092 Bodø, Norway; Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Artic University of Norway, 9038 Tromsø, Norway.
Re-irradiation offers limited benefits due to toxicity and efficacy concerns, especially for second treatments. Further research into evidence-based concepts is needed to expand safe radiotherapy options for patients.
Area of Science:
- Radiation Oncology
- Clinical Cancer Research
Background:
- Re-irradiation presents challenges with a narrow therapeutic window, potentially leading to decreased efficacy and increased toxicity.
- Second re-irradiation is particularly complex, reserved for select patients due to heightened risks.
Purpose of the Study:
- To review uncertainties and future research opportunities in re-irradiation.
- To explore the potential for expanded use of radiotherapy in previously irradiated areas.
Main Methods:
- Literature review summarizing current understanding and challenges in re-irradiation.
- Discussion of normal tissue dose constraints and their ongoing investigation.
Main Results:
- Re-irradiation is often limited to palliative cases like bone metastases.
- Normal tissue dose constraints remain an active area of research.
- Published indications for re-irradiation exist but require careful consideration.
Conclusions:
- Developing evidence-based concepts with acceptable side effect profiles is crucial for increasing patient benefit from re-irradiation.
- Future research should focus on optimizing safety and efficacy for additional radiotherapy courses.
Related Concept Videos
Balancing Redox Equations
Survey Safety
Self-Efficacy
Equilibrium and Balance
Energy Balance
Household Wiring And Electrical Safety

